Details
Category: Volume 06 Issue 06 June 2018
Hits: 1737

Title: Two Novel C-Terminal Frame shift Mutations in the CYB5R3 Gene Lead to Global Growth and Developmental Delay Associated with Recessive Congenital Methemoglobinemia Type II

Authors: Vinod Gupta, Rati Devendra, Aruna Rajendran, Neeraj Sidharthan, Prashant Warang Prabhakar Kedar

 DOI:  https://dx.doi.org/10.18535/jmscr/v6i6.105

Abstract

Deficiency of NADH-cytochrome b5 reductase is the rare cause of recessive congenital methemoglobinemia (RCM) Type-II. It is associated with the mild cyanosis and mental retardation. We have identified three new patients with RCM type-II due to NADH-cytb5r deficiency due and also offered the prenatal diagnosis. All three index cases had cyanosis with severe progressive neurological dysfunction. Methemoglobin level was found in the range of 34.0% to 65% and red blood cell NADH-cytb5r activity were detected only 5 to 30% of normal. The clinical pictures were very similar in all three cases, with severe encephalopathy, microcephaly, generalized dystonia, movement disorders and severe cyanosis. The neurological prognoses are poor; in particular, all the patients do not walk or speak. DNA sequencing result identified two novel mutations. In the first case identified homozygous 2-bp deletion in exon 7 of the CYB5R3 gene, noted as c.604_605delCT (p.Thr202SerfsX98) and in the second case also discovered frame shift homozygous 3-bp deletion mutations (c.766_768delGAG) in exon 9 result in loss of Glutamic acid at codon 256. Third cases showed splice site homozygous mutation (p.Gly76Ser) first time associated with RCM II. Prenatal diagnosis of the fetus in this family revealed same homozygous mutation p.Gly76Ser.

Keywords: Recessive congenital methemoglobinemia (RCM) type II, NADH-cyb5r deficiency, Neurological disorders.

References

  1. R Jaffe.Hereditary methemoglob-inemias associated with abnormalities in the metabolism of erythrocytes. American Journal of Medicine, 41 (1996), pp. 786–798.
  2. J. Percy, N.V. McFerran, & T. R. Lappin, Disorders of oxidized hemogl-obin. Blood Reviews, 19 (2005), pp. 61–68.
  3. T. Prchal, X. T. Gregg. Red cell enzymes. Hematology Am Soc Hematol Educ Program. (2005), pp.19–23
  4. Kugler, A. Pekrun, P. Laspe, B. Erdlenbruch, M. Lakomek.  Molecular basis of recessive congenital methemoglobinemia, types I and II: exon skipping and three novel missense mutations in the NADH-cytochrome b5 reductase (diaphorase 1) gene. Human Mutation, 17 (2001), pp. 348.
  5. Gibson.Introduction: congenital methemoglobinemia revisited. Blood, 100 (2002), pp. 3445–3446.
  6. Dekker, M. H. Eppink, R. Van Zwieten, T. De Rijk, A. F. Remacha, L. K. Law, A.M. Li, K. L. Cheung, W.J. Van Berkel, D. Roos.  Seven new mutations in the nicotinamide adenine dinucleotide reduced-cytochrome b5 reductase gene leading to methemoglobinemia type I. Blood, 97 (2001), pp. 1106–1114.
  7. P. Owen, J. Berens, A.M. Marinaki, H. Ipp, E.H.Harley. Recessive congenital methemoglobinaemia type II, a new mutation which causes incorrect splicing in the NADH–cytochrome b5 reductase gene. Journal of Inherited Metabolic Disease, 20 (1997), pp. 610.
  8. Shirabe, M. T. Landi, M. Takeshita, G. Uziel, E. Fedizzi, N.A.Borgese. A novel point mutation in a 3′ splice site of the NADH–cytochrome b5 reductase gene results in immunologically undetectable enzyme and impaired NADH-dependent ascorbate regeneration in cultured fibroblasts of a patient with type II hereditary methemoglobinemia. American Journal of Human Genetics, 57 (1995), pp. 302–310.
  9. A. Fisher, S. Povey, M.  Bobrow, E. Solomon, Y. Boyd, B.  Carritt.Assignment of the DIA1 locus to chromosome 22. Annals of Human Genetics, 41 (1997),pp. 151–155.
  10. Leroux, C. Junien, J. Kaplan, J. Bamberger. Generalized deficiency of cytochrome b5 reductase in congenital methemoglobinaemia with mental retard-ation. Nature, 258 (1975), pp. 619–620.
  11. Tomatsu, Y. Kobayashi, Y. Fukumaki, T.Yubisui, T.  Orii, Y. Sakaki. The organization and the complete nucleotide sequence of the human NADH-cytochrome b5 reductase gene. Gene, 80 (1989), pp. 353–361.
  12. A. Mannino, T. Pluim, J. Wessler, M.T. Cho, J. Juusola, S.A. Schrier Vergano. Congenital methemoglo-binemia type II in a 5-year-old boy. Clin Case Rep. 7 (2017), pp. 170-178.
  13. P. Warang, P.S. Kedar, C. Shanmukaiah, K. Ghosh, R.B. Colah. Clinical spectrum and molecular basis of recessive congenital methemoglobinemia in India. Clin Genet. 87 (2015), pp. 62-67.
  14. Sambrook, E.F. Fritsch, T. Maniatis.  Molecular Cloning: A Laboratory Manual.2nd ed. Cold Spring Harbor Laboratory; Cold Spring Harbor, NY; (1989).
  15. Hirono.Lipids of myelin, white matter and gray matter in a case of generalized deficiency of cytochrome b5 reductase in congenital methemo-globinemia with mental retardation. Lipids, 15 (1980), pp. 272–275.
  16. A. Evelyn, H. T. Malloy. Microdetermination of oxyhemoglobin, methemoglobin, and sulfhemoglobin in a single sample of blood. J Biol Chem. 126 (1938), pp. 655.
  17. Beutler, E.Red Cell Metabolism. A Manual of Biochemical Methods, 3rd edn. Grune and Stratton, Orlando, FL.(1984).
  18. M. Aalfs, G.B.Salieb-Beugelaar, R.J. Wanders, M.M. Mannens, F.A.Wijburg. A case of methemoglobinemia type II due to NADH-cytochrome b5 reductase deficiency: determination of the molecular basis. Human Mutation, 16 (2000), pp. 18–22.
  19. J. Percy, L.J.Crowley, D.  Roper, T.J. Vulliamy, D.M. Layton, M.J. Barber. Identification and characterization of the novel FAD-binding lobe G75S mutation in cytochrome b5 reductase: an aid to determining recessive congenital methemoglobinemia status in an infant. Blood Cells, Molecules & Diseases, 36 (2006), pp. 81–90.
  20. Shirabe, Y.Fujimoto, T. Yubisui, M. Takeshita. An in-frame deletion of codon 298 of the NADH–cytochrome b5 reductase gene results in hereditary methemoglobinemia type II (generalized type). A functional implication for the role of the COOH-terminal region of the enzyme. Journal of Biological Chemistry, 269 (1994), pp. 5952–5957.
  21. Yilmaz D., Cogulu O., Ozkinay F., and Kavakli K. A novel mutation in the DIA1gene in a patient with methemoglobinemia type II. Am. J. Med. Genet. Part A 2005;133A:101–102. 
  22. Ewenczyk C., Leroux A., Roubergue A., Laugel V., Afenjar A., Saudubray M., et al. Recessive hereditary methaemoglob-inaemia type II: delineation of the clinical spectrum. Brain 2008; 131:760–771.
  23. Higasa K., Manabe J., Yubisui T., Sumimoto H., Pung‐Amritt P., Tanphaichitr V. S., et al. Molecular basis of hereditary methaemoglo-binaemia, types I and II: two novel mutations in NADH‐cytochrome b5 reductase gene. Br. J. Haematol.1998; 103:922–930
  24. Kobayashi Y., Fukumaki Y., Yubisui T., Inoue J., and Sakaki Y. Serine‐proline replacement at residue 127 of NADH cytochrome b5 reductase causes hereditary methemoglobinemia, generalized type. Blood 1990; 75:1408–1413. 
  25. Maran J., Guan Y., Ou C., and Prchal J. T..  Heterogeneity of the molecular biology of methemoglobinemia: a study of eight consecutive patients. Haematologica 2005;90:687–689. 
  26. Puffenberger E. G., Jinks R. N., Sougnez C., Cibulskis K., Willert R. A., Achilly N. P., et al. Genetic mapping and exome sequencing identify variants associated with five novel diseases. PLoS ONE7: 2012;e28936.
  27. Toelle S. P., Boltshauser E., Mossner E., Zurbriggen K., and Eber S.. 2004. Severe neurological impairment in hereditary methaemoglobinaemia type 2. Eur. J. Pediatr. 2004; 163:207–209. 

Corresponding Author

Dr Prabhakar S Kedar, PhD

Scientist D, National Institute of Immunohaematology, Indian Council of Medical Research

13th Floor, New Multistoried Building, K.E.M   Hospital Campus, Parel, Mumbai 400012, India

Tel: + 9122 24138518, Fax: + 9122 24138521, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.